Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, de Leeuw P, De Plaen J F, Deruyttere M, De Schaepdryver A, Dollery C
Inwendige Geneeskunde-Cardiologie, U.Z. Gasthuisberg, Leuven, Belgium.
J Hypertens Suppl. 1985 Dec;3(3):S501-11.
The European Working Party on High Blood Pressure in the Elderly (EWPHE) trial was a double-blind randomized placebo-controlled trial of antihypertensive treatment in patients over the age of 60 years. Entry criteria included both a sitting diastolic blood pressure on placebo treatment in the range 90-119 mmHg and a systolic blood pressure in the range of 160-239 mmHg. The patients (n = 840) were randomized either to active treatment (hydrochlorothiazide + triamterene) or matching placebo. If the blood pressure remained elevated, methyldopa was added to the active regimen and matching placebo in the placebo group. An overall intention-to-treat analysis, combining the double-blind part of the trial and all subsequent follow-up, revealed a non-significant change in total mortality rate (-9%, P = 0.41) but a significant reduction of cardiovascular mortality rate (-27%, P = 0.037). The latter was due to a reduction of cardiac mortality (-38%, P = 0.036) and to a non-significant decrease of cerebrovascular mortality (-32%, P = 0.16). In the double-blind part of the trial, total mortality rate was not significantly reduced (-26%, P = 0.077). Cardiovascular mortality was reduced in the actively treated group (-38%, P = 0.023), due to a reduction of cardiac deaths (-47%, P = 0.048) and to a non-significant decrease of cerebrovascular mortality (-43%, P = 0.15). Deaths from myocardial infarction were reduced (-60%, P = 0.043). Study-terminating morbid cardiovascular events were significantly reduced by active treatment (-60%, P = 0.0064). In the patients randomized to active treatment there were 14 fewer cardiovascular deaths per 1000 patient-years during the double-blind part of the trial. Version 3.
欧洲老年高血压工作组(EWPHE)试验是一项针对60岁以上患者的双盲随机安慰剂对照抗高血压治疗试验。入选标准包括安慰剂治疗时坐位舒张压在90 - 119 mmHg范围内且收缩压在160 - 239 mmHg范围内。患者(n = 840)被随机分为接受活性治疗(氢氯噻嗪 + 氨苯蝶啶)组或匹配的安慰剂组。如果血压仍升高,则在活性治疗方案中添加甲基多巴,并在安慰剂组中添加匹配的安慰剂。一项综合试验双盲部分和所有后续随访的总体意向性分析显示,总死亡率无显著变化(-9%,P = 0.41),但心血管死亡率显著降低(-27%,P = 0.037)。后者归因于心脏死亡率降低(-38%,P = 0.036)和脑血管死亡率无显著下降(-32%,P = 0.16)。在试验的双盲部分,总死亡率未显著降低(-26%,P = 0.077)。活性治疗组的心血管死亡率降低(-38%,P = 0.023),这归因于心脏死亡减少(-47%,P = 0.048)和脑血管死亡率无显著下降(-43%,P = 0.15)。心肌梗死导致的死亡减少(-60%,P = 0.043)。活性治疗使研究终止时的严重心血管事件显著减少(-60%,P = 0.0064)。在试验双盲部分,随机接受活性治疗的患者每1000患者年的心血管死亡减少14例。版本3